A dental software founder would take more customer capital to hire leaders sooner

Oryx’s dentist investors helped it grow without venture capital. Nursa and Roon’s founders explained when outside financing helped them accelerate, recruit and adapt.

Author
HDM Staff
Save
Share
Illuminated HLTH lettering and event entrance arch
Event branding at the entrance to HLTH USA 2026 in Las Vegas. Photo credit: HLTH USA 2026

    Rania Saleh’s early investors were dentists who already used the software she was building. They wanted the platform to improve, and they were prepared to put up more money than she took. Years later, the founder and CEO of Oryx Dental Software could see what she might have done with the difference. She would have hired a leadership team sooner, giving individual executives responsibility for functions that she and her small team had been carrying themselves.

    Saleh described the decision during The Case for Bootstrapping vs. Raising Early, a Nov. 17 panel on the Startup Acceleration Stage in Las Vegas. Ashley Tyrner-Dolce, founder of FarmboxRx and an operating partner at HLM Investment Partners, moderated. Curtis Anderson, founder and CEO of Nursa, joined Saleh and Rohan Ramakrishna, a neurosurgeon and co-founder of physician network Roon. Their companies faced three different problems when it came to financing. Oryx needed dentists to see a reason to switch software. Nursa got its product working before COVID-19 accelerated adoption. Roon raised from the beginning to buy time to build a network.

    Dental practices had a stake in the product

    Saleh started Oryx in 2016 after encountering problems in her own practice. Dentists were still reliant on software installed in their offices, she said, and many had little appetite for a change. Investors she approached could not see the opportunity. Dentists who were already using the product could. They offered her capital with the expectation that the company would keep making the software they used more useful. “It was complete alignment,” she said.

    Saleh said the platform now serves 20,000 clinical team members and that Oryx had grown without private equity or venture capital funding. The distinction matters because the company did accept money from angels. The choice was how much to take and from whom. In retrospect, the deal she wishes she had made was to take more of the capital existing users had offered. The cash could have brought forward the point at which leaders could own individual functions and free up the people who had been doing several jobs.

    If she were starting today, Saleh said she would “probably have raised earlier.” She sees dental practices more willing to change systems in part because they want AI capabilities. She recalled how one competitor’s large fundraise initially looked like a threat. Its spending on explaining cloud-based dental software helped more practices understand the category, and some looked at Oryx alongside the better-funded firm. Even where one business pays to introduce a category, customers can still choose among products.

    Nursa waited until the demand changed

    Anderson started Nursa before COVID-19, when adoption in healthcare could take time and facilities were accustomed to working with staffing agencies. He used the period to test whether a platform could match them with clinicians. During the pandemic, facilities faced more immediate staffing needs and became willing to trust a different way to fill shifts. Anderson raised outside funding when he could see what the company needed to do with it. His rule was to “raise to accelerate.”

    The financing could help Nursa meet demand. The company also had to build the organization that would handle it. Anderson described a difficult transition from a small team to a much larger operation. That experience informed his advice to founders whose competitors have just raised a large round. “There are a lot of problems money doesn’t solve,” he said. The competitor’s announcement can prompt a useful look at a startup’s priorities, but how the company distinguishes its product and keeps it working at higher volume remains the team’s work.

    Anderson said he also looked for investors who could demonstrate that they understood healthcare operations and had held investments for a decade or longer. He wanted to see how they had actually behaved in those deals. Nursa had raised amid extraordinary conditions, with little visibility into how quickly demand or financing conditions would change again. An investor comfortable with that uncertainty would be in a better position to help once the urgency receded.

    Roon bought time to change course

    Ramakrishna wanted doctors to be able to communicate and collaborate in a common network, with some of the character of a physicians’ lounge. He said the business made sense at scale, and the founding team needed enough money to address several risks at once. They had to learn whether they could work together, make and ship a product and recruit the people who could help it grow.

    Funding created time to make “shots on goal,” Ramakrishna said. He also saw an immediate recruiting benefit from having recognizable firms on the capitalization table. Candidates who knew the investors would look more closely at the company. That attention was helpful as Roon tried to recruit for an idea whose final form was still changing. The founders gave up some ownership in exchange.

    Roon raised about 20 to 30 percent more than it initially thought it needed at seed, Ramakrishna said. The company later changed direction, and financial markets were cooler by the time it sought its Series A. He called the extra money a “cushion.” He also said that Roon’s first financing closed in about two weeks, while its Series A took nearly two months. The difference explains why a financing plan built around one fast close can leave a company with little room to adapt.

    Test what an investor brings before taking the check

    Tyrner-Dolce asked the founders how they evaluate investors beyond the terms on the page. Ramakrishna described speaking with founders who had already taken money from the same firms. Those conversations helped him judge whether a partner would make introductions, help with recruiting and contribute at board meetings without pulling an operating team away from its work. Saleh described giving prospective investors a small real assignment, such as helping identify a candidate for a job, to see both how they understood her company and whom they could reach. Anderson wanted evidence from past investments that a partner had stayed engaged over time.

    The founders’ answers turn on what a check would allow the company to do next. For Oryx it could have brought in senior executives while the dentist customers behind the investment were still eager to help. For Nursa it gave a working product the ability to serve a sudden increase in demand. For Roon it made it possible to experiment and recruit while building a network. In each case, the practical question came before the size of the round. What work would happen sooner, and who would be there to help when the conditions that justified the investment changed?